Clinical trials: Prostate Disease
Prostate Cancer Recurrent, Prostate Cancer
Epidiolex (CBD) in Patients With Biochemically Recurrent Prostate Cancer
The purpose of this phase I/Ib study is to determine the safety profile of Epidiolex (CBD oil) in biochemically recurrent prostate cancer patients. The study consists of a dose escalation part and dose expansion part.
- Conditions
- Prostate Cancer Recurrent, Prostate Cancer, Prostate Adenocarcinoma
- Trial name
- NCT04428203
- Testing
- Epidiolex Oral Liquid Product
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Zin W Myint
Enlarged Prostate
3D Rotational CT Angiogram With Embolization Guidance and CBCT in Prostatic Artery Embolization
The purpose of this research study is to learn about how cone-beam Computerized Tomography scans (X-ray images taken from different angles) work together with an embolization guidance software (helps the doctor see the arteries…
- Trial name
- NCT03164629
- Testing
- cone-beam CT 3D Emboguide
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Miami
Prostate Cancer
Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer
This was an extension study for the study FE200486 CS14 (NCT00116779). Each participant was to be treated until he was discontinued or withdrawn from the study, or a marketing authorization for degarelix had been obtained.
- Trial name
- NCT00117286
- Testing
- Degarelix
- Where
- 22 sites in United States, Canada
- Volunteers
- 57 people
- Sponsor
- Ferring Pharmaceuticals
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma
PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer
This phase I trial studies side effects and best dose of PSCA-chimeric antigen receptor (CAR) T cells in treating patients with prostate stem cell antigen positive (PSCA+) castration resistant prostate cancer that has spread to…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- NCT03873805
- Testing
- Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- City of Hope Medical Center
Metastatic Castration-resistant Prostate Cancer
Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199)
This is a study of pembrolizumab (MK-3475) in participants with metastatic castration-resistant prostate cancer (mCRPC). Participants will be enrolled into one of five cohorts: Cohort 1 (participants with programmed cell death…
- Trial name
- NCT02787005
- Testing
- Pembrolizumab
- Volunteers
- 388 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostate Cancer
Study of SU11248 in Men With Advanced Prostate Cancer
There are nearly 30,000 deaths per year in the United States from prostate cancer, making this a large and important target patient population for new cancer treatments.
- Trial name
- NCT00299741
- Testing
- Sunitinib
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Massachusetts General Hospital
Recurrent Prostate Cancer, Stage I Prostate Cancer
Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer
This phase II trial studies how well lapatinib ditosylate works in treating patients with a rising prostate-specific antigen (PSA), a protein made by the prostate gland, indicating that prostate cancer has come back after…
- Conditions
- Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
- Trial name
- NCT00103194
- Testing
- lapatinib ditosylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- National Cancer Institute (NCI)
Anemia, Breast Cancer
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
This is a multicenter, international, prospective, observational study of patients who are receiving systemic chemotherapy for solid tumour cancers (breast, colorectal, ovarian, prostate, lung, bladder, endometrial, renal…
- Conditions
- Anemia, Breast Cancer, Cancer, Colorectal Cancer
- Trial name
- NCT01444456
- Where
- 117 sites in Austria, Belgium and 7 more
- Volunteers
- 1,262 people
- Sponsor
- Amgen
Prostate Cancer
Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer
The purpose of this study is to evaluate the safety of a new drug- sorafenib, which is to be administered at the same time as standard treatment, which includes hormonal therapy and external beam radiotherapy.
- Trial name
- NCT00924807
- Testing
- Leuprolide acetate, Bicalutamide, Sorafenib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Beth Israel Medical Center
Prostate Adenocarcinoma, Stage IIA Prostate Cancer AJCC v7
Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer
This randomized phase I/II trial studies giving leuprolide acetate or goserelin acetate together with or without vismodegib followed by surgery to see how well they work in treating patients with prostate cancer that has spread…
- Conditions
- Prostate Adenocarcinoma, Stage IIA Prostate Cancer AJCC v7, Stage IIB Prostate Cancer AJCC v7
- Trial name
- NCT01163084
- Testing
- Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide Acetate
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)
The purpose of this study is to assess the safety and activity of ARN-509 in men with advanced castration resistant prostate cancer.
- Trial name
- NCT01171898
- Testing
- ARN-509 (Phase 1), ARN-509 (Phase 2)
- Where
- 15 sites in United States
- Volunteers
- 127 people
- Sponsor
- Aragon Pharmaceuticals, Inc.
Gastric Adenocarcinoma, Esophageal Cancer
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
The primary objective in Phase I is to evaluate the safety and tolerability of sacituzumab govitecan-hziy (SG) as a single agent administered in 21-day treatment cycles in previously treated participants with advanced epithelial…
- Conditions
- Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT01631552
- Testing
- Sacituzumab Govitecan-hziy (SG)
- Where
- 12 sites in United States
- Volunteers
- 515 people
- Sponsor
- Gilead Sciences
Stage I Prostate Cancer, Stage IIA Prostate Cancer
Green Tea Extract in Treating Patients With Low-Risk Prostate Cancer
This randomized phase II trial studies how well green tea extract works in treating patients with low-risk prostate cancer. Green tea extract contains ingredients that may prevent or slow the growth of certain cancers.
- Conditions
- Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
- Trial name
- NCT01928485
- Testing
- active surveillance, Sunphenon, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Sanjay Gupta PhD
Healthy
Novel 13C Carotenoids for Absorption and Metabolism Studies in Humans
Tomatoes contain several compounds which may be beneficial for human health and prevention of disease, although this relationship is poorly understood and very controversial.
- Trial name
- NCT01692340
- Testing
- Isotopically labeled lycopene, phytoene or phytofluene
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Prostate Cancer
High Dose Rate Prostate Brachytherapy: Dose Escalation to Dominant Intra-prostatic Nodule
This study will investigate the feasibility of using technology of ultrasound guided HDR brachytherapy to focally increase dose to regions within the prostate that are heavily infiltrated with cancer.
- Trial name
- Dosepainting (NCT01605097)
- Testing
- HDR interstitial brachytherapy
- Where
- Canada
- Volunteers
- 26 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer
An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to assess safety and efficacy of nivolumab in combination with rucaparib, docetaxel, or enzalutamide in participants with castration-resistant prostate cancer that has spread.
- Trial name
- CheckMate 9KD (NCT03338790)
- Testing
- nivolumab, docetaxel, enzalutamide
- Where
- 66 sites in United States, Argentina and 9 more
- Volunteers
- 292 people
- Sponsor
- Bristol-Myers Squibb
Prostate Cancer
Vitamin D Supplementation in Veterans With Early-Stage Prostate Cancer
Vitamin D promotes the differentiation of prostate cancer cells, maintains the differentiated phenotype of prostate epithelial cells, and can induce prostate cancer cell death, raising the possibility that vitamin D deficiency…
- Trial name
- vit D & PCa (NCT00953225)
- Testing
- vitamin D3
- Where
- 2 sites in United States
- Volunteers
- 83 people
- Sponsor
- VA Office of Research and Development
Prostate Cancer
Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer
RATIONALE: Giving samarium Sm 153 lexidronam pentasodium and 3-dimensional (3-D) conformal radiation therapy or intensity-modulated radiation therapy may keep prostate cancer from growing in patients with rising prostate-specific…
- Trial name
- NCT00551525
- Testing
- Radiotherapy, Samarium 153
- Where
- 29 sites in United States
- Volunteers
- 67 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer
A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer
The purpose of the study was to contribute, along with other such dose-finding studies, to the identification of the most effective treatment regimen for a one month depot injection of degarelix in the treatment of prostate…
- Trial name
- NCT00116779
- Testing
- Degarelix
- Where
- 35 sites in United States, Canada
- Volunteers
- 127 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer
Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy
The study will have two treatment groups, evaluating two Degarelix doses. First dose is the initial dose followed by a maintenance dose given every three months.
- Trial name
- NCT00468286
- Testing
- Degarelix
- Where
- 29 sites in United States, Canada and 3 more
- Volunteers
- 133 people
- Sponsor
- Ferring Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.